002772.SHE Tianshui Zhongxing Bio-technology Co Ltd
- Market cap
- CNY 2.93B
- P/E
- 13.5x
- P/B
- 0.82x
- ROE
- 3.2%
- Dividend yield
- 3.84%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002772.SHE undervalued?
Graham number002772.SHE trades 29.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianshui Zhongxing Bio-technology Co Ltd fundamental analysis
No fundamental analysis for Tianshui Zhongxing Bio-technology Co Ltd yet.
Tianshui Zhongxing Bio-technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianshui Zhongxing Bio-technology Co Ltd
Tianshui Zhongxing Bio-technology Co.,Ltd., together with its subsidiaries, engages in the research and development, production and sales of edible mushrooms in China and internationally. It offers enoki and button mushrooms; cordyceps militaris; and cordyceps sinensis. The company also engages in agriculture planting, investment management, and real estate development businesses. Tianshui Zhongxing Bio-technology Co.,Ltd. was founded in 2005 and is headquartered in Tianshui…
Full company profileTianshui Zhongxing Bio-technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianshui Zhongxing Bio-technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 585M | 740M | 926M | 1.16B | 1.48B | 1.56B | 1.97B | 1.93B | 1.94B | 2.10B | 2.14B |
| Gross Profit | 229M | 233M | 257M | 276M | 408M | 288M | 498M | 437M | 390M | 586M | 550M |
| Operating Income | 153M | 139M | 114M | 73.7M | 192M | 83.4M | 166M | 159M | 125M | 328M | 312M |
| EBITDA | 234M | 237M | 278M | 335M | 499M | 393M | 525M | 512M | 490M | 584M | 181M |
| Net Income | 159M | 142M | 112M | 68.4M | 189M | 55.0M | 158M | 160M | 128M | 335M | 112M |
| EPS | 0.47 | 0.38 | 0.30 | 0.19 | 0.56 | 0.14 | 0.40 | 0.39 | 0.33 | 0.89 | 0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 3.21B | 4.09B | 4.11B | 5.01B | 5.58B | 6.55B | 6.57B | 6.07B | 6.19B | 7.09B | 7.55B |
| Total Liabilities | 922M | 1.46B | 1.48B | 2.41B | 2.85B | 3.30B | 3.18B | 2.64B | 2.87B | 3.43B | 4.09B |
| Shareholders' Equity | 2.28B | 2.62B | 2.63B | 2.60B | 2.73B | 3.25B | 3.38B | 3.43B | 3.32B | 3.53B | 3.46B |
| Cash & Short-term Investments | 349M | 1.17B | 475M | 1.64B | 1.90B | 1.86B | 1.70B | 1.32B | 1.52B | 1.80B | 1.75B |
| Total Debt | 484M | 1.10B | 1.12B | 2.01B | 2.45B | 2.75B | 2.60B | 2.08B | 1.68B | 2.89B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 233M | 207M | 232M | 359M | 389M | -414M | 494M | 525M | 495M | 504M | - |
| Capital Expenditure | 480M | 502M | 652M | 664M | 380M | 286M | 246M | 107M | 245M | 552M | 567M |
| Free Cash Flow | -246M | -295M | -420M | -304M | 9.58M | -700M | 248M | 395M | 249M | -48.0M | -335M |
| Ratios | |||||||||||
| ROE | 6.9% | 5.4% | 4.3% | 2.6% | 6.9% | 1.7% | 4.7% | 4.6% | 3.9% | 9.5% | 3.2% |
| ROA | 4.9% | 3.5% | 2.7% | 1.4% | 3.4% | 0.8% | 2.4% | 2.6% | 2.1% | 4.7% | 1.5% |
| Net Profit Margin | 27.1% | 19.2% | 12.1% | 5.9% | 12.7% | 3.5% | 8.0% | 8.3% | 6.6% | 16.0% | 5.2% |
| Debt to Equity | 0.21x | 0.42x | 0.43x | 0.77x | 0.90x | 0.85x | 0.77x | 0.61x | 0.51x | 0.82x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tianshui Zhongxing Bio-technology Co Ltd dividends
- Dividend yield
- 3.84%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 33.6%
- Ex-dividend date
- Oct 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 112M | 0.30 | 33.6% |
| 2024 | CNY 200M | 0.51 | 155.9% |
| 2023 | CNY 211M | 0.52 | 132.1% |
| 2022 | CNY 39.3M | 0.10 | 24.8% |
| 2021 | CNY 34.8M | 0.09 | 63.3% |
| 2020 | CNY 33.9M | 0.10 | 17.9% |
| 2019 | CNY 35.3M | 0.10 | 51.7% |
| 2018 | CNY 49.8M | 0.13 | 44.5% |
| 2017 | CNY 54.7M | 0.15 | 38.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20.51299:10 on Apr 15, 2016.
Who owns Tianshui Zhongxing Bio-technology Co Ltd
- Insiders 45.41%
- Institutions 6.86%
- Public & others 47.74%
- Shares outstanding 375M
- Free float 216M
Tianshui Zhongxing Bio-technology Co Ltd company profile
- Company name
- Tianshui Zhongxing Bio-technology Co Ltd
- Ticker
- 002772.SHE
- ISIN
- CNE1000020B6
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 9,181
- Fiscal year end
- December
- Address
- Tianshui National Agricultural Science and Technology Park, Tianshui, China, 741030
- Phone
- 86 93 8285 1611
- Website
- tszxjy.cn
About Tianshui Zhongxing Bio-technology Co Ltd
Tianshui Zhongxing Bio-technology Co.,Ltd., together with its subsidiaries, engages in the research and development, production and sales of edible mushrooms in China and internationally. It offers enoki and button mushrooms; cordyceps militaris; and cordyceps sinensis. The company also engages in agriculture planting, investment management, and real estate development businesses. Tianshui Zhongxing Bio-technology Co.,Ltd. was founded in 2005 and is headquartered in Tianshui, China.
Tianshui Zhongxing Bio-technology Co Ltd management
7- Mr. Boshu GaoChairman · born 1974
- Mr. Liang LiuGM & Director · born 1974
- Mr. Chunhui TaoVice Chairman & Deputy GM · born 1987
- Mr. Min LiChief Financial Officer · born 1986
- Ms. Xiaoli QianSecretary of the Board of Directors · born 1986
- Mr. Jinjun ZhouDeputy General Manager · born 1970
- Mr. Shou Fu ZhangDeputy General Manager · born 1975